Sophie Weill

Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells

Aïda Ghoul, Maria Serova, Lucile Astorgues‐Xerri et al. · Cancer Research · 2009 · 49 citations · Full text

Pathology, Cancer Biology, Tumor Biology +17

Pharmacokinetics, Metabolism, and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors

Angélo Paci, Keyvan Rezaï, Alain Deroussent et al. · Drug Metabolism and Disposition · 2006 · 15 citations

Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans

François Lokiec, Joelle Santoni, Sophie Weill et al. · Anti-Cancer Drugs · 1996 · 12 citations

Thrombosis, Phenobarbital Administration, Therapeutic Drug Monitoring +11

Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study

Étienne Brain, Keyvan Rezaï, Sophie Weill et al. · Cancer Chemotherapy and Pharmacology · 2006 · 12 citations

Better Understanding, Pharmacology, Pharmacotherapy +6

Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP

E. Baudry, Samuel Huguet, Anne‐Laure Couderc et al. · Cancer Chemotherapy and Pharmacology · 2019 · 10 citations

Therapeutic Drug Monitoring, Elderly Patients, Pharmacotherapy +4